Enbrel gets black-box infection warning

Enbrel's new black box is now official. Wyeth and Amgen have put the final touches on a boxed warning about tuberculosis and other life-threatening illness; the label states that patients using the drug have contracted infections that led to hospitalization and death. The drug is primarily used to treat psoriasis, but also is used for rheumatoid arthritis and other autoimmune disorders.

Amgen and Wyeth co-market Enbrel in the U.S. and Canada. The drug posted $3.2 billion in sales in 2007.

- see the CNN Money coverage

ALSO: According to the latest CEO ranking by Forbes magazine, which measured performance against pay for 175 company chiefs, Amgen's Kevin Sharer came in near the bottom of the barrel, at 169th. Report

Related Articles:
Alzheimer's: A new indication for Enbrel?
Enbrel gets 'black box' infection warning

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.